Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The identification of brain-targeted autoantibodies in children with autism spectrum disorder (ASD) raises the possibility of autoimmune encephalopathy (AIE). Intravenous immunoglobulin (IVIG) is effective for AIE and for some children with ASD. Here, we present the largest case series of children with ASD treated with IVIG. Through an ASD clinic, we screened 82 children for AIE, 80 of them with ASD. IVIG was recommended for 49 (60%) with 31 (38%) receiving the treatment under our care team. The majority of parents (90%) reported some improvement with 71% reporting improvements in two or more symptoms. In a subset of patients, Aberrant Behavior Checklist (ABC) and/or Social Responsiveness Scale (SRS) were completed before and during IVIG treatment. Statistically significant improvement occurred in the SRS and ABC. The antidopamine D2L receptor antibody, the anti-tubulin antibody and the ratio of the antidopamine D2L to D1 receptor antibodies were related to changes in the ABC. The Cunningham Panel predicted SRS, ABC, parent-based treatment responses with good accuracy. Adverse effects were common (62%) but mostly limited to the infusion period. Only two (6%) patients discontinued IVIG because of adverse effects. Overall, our open-label case series provides support for the possibility that some children with ASD may benefit from IVIG. Given that adverse effects are not uncommon, IVIG treatment needs to be considered cautiously. We identified immune biomarkers in select IVIG responders but larger cohorts are needed to study immune biomarkers in more detail. Our small open-label exploratory trial provides evidence supporting a neuroimmune subgroup in patients with ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, these authors found a correlation between CaMKII reduction and clinical improvement with IVIG treatment administered every 4 weeks.”
From An updated review of pediatric autoimmune neuropsychiatric disorders associated with Streptococcus/pediatric acute-onset neuropsychiatric syndrome, also known as idiopathic autoimmune encephalitis: What the allergist should know (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A subsequent study by Connery et al 31 reported a positive predictive response to IVIG treatment in patients with IAE, with overall accuracy between 81% and 88% and a sensitivity ranging between 90% and 100% and specificity between 67% and 75%.”
The cited source says what the claim attributes to it.
In the citing paper
“The CaMKII biomarker subsequently increased, which was associated with clinical deterioration of the patient's condition when IVIG was adjusted to every 6 weeks, suggesting this biomarker may be useful for monitoring dose adjustments for patients treated with IVIG.31”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165
Synaptic Vesicle Phosphoproteins and Regulation of Synaptic Function
Greengard, P., Valtorta, F., Czernik, A. J., & Benfenati, F. (1993) · Science · doi:10.1126/science.8430330 · Cited by 1,312
Constantino, J. N. (2013) · Encyclopedia of Autism Spectrum Disorders · doi:10.1007/978-1-4419-1698-3_296 · Cited by 908
Wild-type microglia arrest pathology in a mouse model of Rett syndrome
Derecki, N. C., Cronk, J. C., Lu, Z., Xu, E., Abbott, S. B. G., Guyenet, P. G., & Kipnis, J. (2012) · Nature · doi:10.1038/nature10907 · Cited by 607
Perlmutter, S. J., Leitman, S. F., Garvey, M. A., Hamburger, S., Feldman, E., Leonard, H. L., & Swedo, S. E. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12297-3 · Cited by 556
Reichow, B., Barton, E. E., Boyd, B. A., & Hume, K. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009260.pub2 · Cited by 543
Rossignol, D. A., & Frye, R. E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.165 · Cited by 543
Self-citationZablotsky, B., Black, L. I., Maenner, M. J., Schieve, L. A., & Blumberg, S. J. (2015) · PubMed · Cited by 535
Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis
Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R., Hickie, I. B., & Guastella, A. J. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.59 · Cited by 466
Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea
Kirvan, C. A., Swedo, S. E., Heuser, J. S., & Cunningham, M. W. (2003) · Nature Medicine · doi:10.1038/nm892 · Cited by 463
Self-citation
Cited by
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 458
Al-Beltagi, M. (2021) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v10.i3.15 · Cited by 273
Emerging biomarkers in autism spectrum disorder: a systematic review
Frye, R. E., Vassall, S., Kaur, G., Lewis, C., Karim, M., & Rossignol, D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.53 · Cited by 206
Self-citationEndres, D., Pollak, T. A., Bechter, K., Denzel, D., Pitsch, K., Nickel, K., Runge, K., Pankratz, B., Klatzmann, D., Tamouza, R., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-021-01700-4 · Cited by 150
Modern Biomarkers for Autism Spectrum Disorder: Future Directions
Jensen, A., Lane, A. L., Werner, B. A., McLees, S. E., Fletcher, T. S., & Frye, R. E. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00600-7 · Cited by 127
Self-citation
Metadata
- Authors
- Connery, K., Tippett, M., Delhey, L. M., Rose, S., Slattery, J. C., Kahler, S. G., Hahn, J., Kruger, U., Cunningham, M. W., Shimasaki, C., & Frye, R. E.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- Rensselaer Polytechnic Institute (US)
- University of Oklahoma Health Sciences Center (US)
- Oklahoma Department of Transportation (US)
- Barrow Neurological Institute (US)
- Corresponding author
- Frye, Richard E.
- Venue
- Translational Psychiatry
- Published
- 2018-08-10
- Volume
- 8
- Issue
- 1
- Pages
- 148-148
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC6086890
- OpenAlex
- W2885292966
- Cited by
- 64
- References
- 70
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 1
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Autism Research Institute
- Arkansas Biosciences Institute
- Children’s Hospital of Wisconsin Research Institute
- Topics
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- intravenous immunoglobulin, autoimmune encephalopathy, autism spectrum disorder, anti-tubulin antibodies, Aberrant Behavior Checklist, Social Responsiveness Scale, treatment response, immunological markers, adverse effects
- MeSH terms
- Autism Spectrum Disorder, Adolescent, Ambulatory Care Facilities, Arkansas, Child, Child, Preschool, Encephalitis, Female, Humans, Male, Case-Control Studies, Immunoglobulins, Intravenous, Receptors, Dopamine D1, Hashimoto Disease, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. https://app.cochat.ai/papers/10.1038/s41398-018-0214-7
- The paper
- Connery, K., Tippett, M., Delhey, L. M., Rose, S., Slattery, J. C., Kahler, S. G., Hahn, J., Kruger, U., Cunningham, M. W., Shimasaki, C., & Frye, R. E. (2018). Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Translational Psychiatry. https://doi.org/10.1038/s41398-018-0214-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.